RAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy

The Measure is not clinical guidelines, does not establish a standard of medical care, and has not been tested for all potential applications.
The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.
Commercial uses of the Measure require a license agreement between the user and the American Society of Clinical Oncology (ASCO) and prior written approval of ASCO. Neither ASCO nor its members shall be responsible for any use of the Measures.
ASCO encourages use of the Measures by other health care professionals, where appropriate.
THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.
© 2020 American Society of Clinical Oncology. All Rights Reserved. 
Limited proprietary coding is contained in the Measure specification for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASCO and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specification.
CPT® contained in the Measures specifications is copyright 2004-2019 American Medical Association. LOINC® copyright 2004-2018 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2018 College of American Pathologists. All Rights Reserved.